Kim LufkinGHTC
Kim Lufkin is a communications officer at GHTC.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
The House Appropriations Committee has released its fiscal year (FY) 2014 State and Foreign Operations Appropriations bill, which is under consideration today in subcommittee. The bill contains $1.4 billion for the US Agency for International Development—a reduction of $172 million from the FY2013 level.
The World Health Organization has added three new drugs developed by GHTC member Drugs for Neglected Diseases initiative to its Essential Medicines List for Children.
A new House bill would exempt US Food and Drug Administration (FDA) user fees from sequestration. The FDA's budget is heavily supported by user fees from the industries it regulates, and sequestration would cut about $85 million from the agency's budget in 2013 by hitting these fees.
A new guide from the Council on Health Research for Development aims to provide low- and middle-income countries with greater control over research collaborations. The guidance covers issues such as intellectual property rights, ownership of data and samples, capacity building, technology transfer, compensation for indirect costs, and the legislative context of research contracts.
The National Center for Advancing Translational Sciences recently awarded a total of $12.7 million to nine research projects aimed at discovering new uses for drugs that failed in previous clinical trials.
The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) announced the launch of a soil-transmitted helminth vaccine research program. The program will advance candidates for ascariasis (roundworm) and trichuriasis (whipworm) infections and incorporate them into existing hookworm and schistosomiasis under development by the Sabin PDP to create a vaccine against all four major human helminth infections.